22 results about "Intradermal injection" patented technology

The application belongs to the technical field of medical apparatus and specifically discloses an injection positioning device for endocrinology department, which comprises a mounting ring and a lifting injection ring for clamping an injection pen, the lifting injection ring can be lifted along a limiting column vertically arranged on the mounting ring, a first compression spring for driving the lifting injection ring to descend is arranged between the mounting ring and the lifting injection ring, a force storage engagement mechanism for locking the lifting injection ring at a force storage position, a three-point pressing parallel trigger mechanism for sensing the contact state with the skin surface and a torque release mechanism for releasing the force storage engagement mechanism according to the state of the three-point pressing parallel trigger mechanism are further included. The force storage release mechanism with the conditional locking and triggering functions is arranged, and the locking state is released only when the device is pressed to be close to the skin and the axis of the injection pen is perpendicular to the skin, so that the force storage mechanism is triggered to drive the injection pen to complete the puncture action, and the intradermal injection risk caused by the angle inclination is eliminated.

The present disclosure provides a double-stranded siRNA with lipophilic modification. The modified siRNA molecules exhibit excellent in vivo distribution and delivery efficiency via intrathecal injection, intradermal injection, or other administration routes. The molecules effectively knock down target gene expression while maintaining good tolerability and safety. The present disclosure further provides a preparation method of siRNA with lipophilical modification, a pharmaceutical composition, and application of the same in the preparation of a medicament for treating a TNF-α-mediated disease or disorder.

The invention discloses a 3D nano microneedle electrode for improving glucose monitoring performance and a preparation method and application thereof, and relates to the technical field of biosensing. The 3D nanometer microneedle electrode for improving the glucose monitoring performance comprises a microneedle electrode base material and an electrode sensing material, the microneedle electrode base material is a stainless steel intradermal injection needle, the microneedle electrode base material is filled with a conductive filler, the conductive filler comprises carbon paste and silver paste, and the electrode sensing material comprises an inner layer structure and a surface layer structure. The inner-layer structure is a conductive nano-carrier, and the surface-layer structure is a compound enzyme layer. The invention also provides a preparation method of the 3D nano microneedle electrode for improving the glucose monitoring performance. The utilization rate and catalytic activity of Prussian blue are improved, electron transfer is accelerated, and the problems that a traditional glucose sensor is low in electron transfer efficiency, insufficient in stability and limited in detection range and accuracy are effectively solved.

This invention belongs to the field of biomedical technology, specifically relating to a delivery system for type III collagen mRNA and its applications. The nucleic acid delivery system of this invention includes a delivery carrier and a delivered nucleic acid, wherein the nucleic acid is collagen mRNA, and the delivery carrier includes one or more of modified amino acids, growth factors, and polymeric materials. Through intradermal injection, the delivery system of this invention can be administered to the dermal layer of the skin and enter relevant cells, utilizing endogenous cellular proteins to achieve mRNA transfection, forming natural human type III collagen. This invention avoids the immunogenicity risks and structural inactivation problems associated with exogenous collagen injections, and can efficiently and safely replenish non-regenerative type III collagen in tissues. It can be used for various indications such as treating skin aging, promoting wound healing, reducing scar formation, and improving vascular elasticity.

The invention discloses a T cell receptor immune stimulator as well as a preparation method and application thereof, and the immune response generated by a'full-spectrum 'T cell receptor antigen is utilized to realize the elimination and inhibition of self-reactive TCR (T cell receptor), so that the immune regulation effect is realized. The T cell immunostimulant induces immune response through intradermal injection, generates anti-uniqueness T cells aiming at an autoreactive T cell antigen receptor (TCR), selectively kills the autoreactive T cells or inactivates the autoreactive T cells to play a therapeutic role.

The present application relates to a kind of intradermal injection training systems, including wrist model, annular light transceiver component, ultrasonic unit and processing module.In the case where puncture needle pierces wrist model, puncture needle forms first projection in annular light transceiver component under the light irradiation of annular light transceiver component, and forms second projection under the ultrasonic monitoring of ultrasonic unit.Processing module establishes three-dimensional coordinate system based on the data of acquired first projection and second projection to present puncture needle in virtual space in three dimensions.The intradermal injection training system of the present application is provided with processing module that can calculate and simulate the angle and depth of actual puncture needle, by obtaining the first projection and second projection of puncture needle, according to the position, angle and length of projection distribution, it can construct injection angle and depth in three-dimensional level, so as to be in the form of video image or picture in real time by display module Show to training personnel and / or teaching staff, to improve the efficiency and effect of training.

The invention relates to a PTGER4 agonist for treating atopic dermatitis or a medicine for promoting the overexpression of PTGER4, the medicine for promoting the overexpression of PTGER4 is RNA (Ribonucleic Acid) for the overexpression of PTGER4, the sequence of the RNA is shown as SEQ ID NO.1, and the PTGER4 agonist is L-902, 688. According to the PTGER4 agonist and the PTGER4 overexpression adeno-associated virus, the PTGER4 activation or overexpression effect is achieved through local external application or intradermal injection, atopic dermatitis symptoms are improved, and the PTGER4 agonist and the PTGER4 overexpression adeno-associated virus have wide application prospects in the aspect of clinical treatment of atopic dermatitis.

A method of treating vertigo in a patient in need thereof comprises administering a botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous / intradermal injection. The subcutaneous / intradermal injection may be administered to and / or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and a sacral nerve of the patient.

Described are compositions, kits and methods for preventing, minimizing the risk of, or treating a microbial infection at a wound or surgical site. The method comprises injecting a combination of a therapeutically effective microdose of a microbial agent and a local anesthetic into the dermis layer of the skin. The composition can be administered by medical personnel, provided by non-clinical personnel, or self-administered.

This invention discloses the application of gels and fibroblasts in the preparation of drugs for treating skin defects, belonging to the fields of biomedicine and tissue engineering technology. Early application provides a moist microenvironment to accelerate epithelial migration and achieve rapid wound closure; later, intradermal injection of fibroblasts promotes collagen remodeling and angiogenesis; ultimately achieving synergistic optimization of early rapid closure and later dermal regeneration.

Disclosed in the present invention is a double-stranded siRNA having a lipophilic modification. The modified siRNA molecule, via intrathecal injection, intradermal injection and other administration modes, achieves an excellent in-vivo distribution performance and delivery efficiency, and has a good tolerability and safety while effectively knocking down the expression of a target gene. Further disclosed in the present invention are a method for preparing the siRNA having a lipophilic modification, a pharmaceutical composition, and the use thereof in the preparation of a drug for treating a TNF-α-mediated disease or condition.

The invention discloses an auxiliary device for medicine injection in the field of medicine injection auxiliary instruments, the auxiliary device comprises a fixing assembly and a guide assembly, the fixing assembly comprises two connecting plates and a fixing plate fixed between the connecting plates; the guide assembly comprises a guide plate and a guide cylinder, rotating rods are arranged on the two sides of one end of the guide plate, and the two rotating rods are rotationally connected to the opposite faces of the two connecting plates correspondingly; the other end of the guide plate is fixedly connected with a fixing rod, the other end of the fixing rod is fixedly connected with the guide cylinder, the upper surface of the guide plate is provided with a guide groove for a syringe needle to pass through, the guide groove and the axis of the guide cylinder are located on the same straight line, and the upper surface of the guide plate is slidably connected with a connecting block in the length direction of the guide plate. A screw is in threaded connection with the fixing plate and penetrates through the fixing plate to be rotationally connected with the connecting block, and inclination angle scales are arranged at the end, close to the guide cylinder, of the connecting plate. By means of the auxiliary device, medicine can be injected into the skin of the foot or the hand of a dead individual more accurately.

The present invention relates to the use of botulinum toxins for the treatment of hyperpigmentation conditions. The use includes intracutaneously injecting botulinum toxin into the skin of a patient with hyperpigmentation at a specific depth, volume and dose to specifically target the epidermal layer and the upper dermal layer. For example, an intradermal injection of botulinum toxin according to the invention may be used to treat chloasma.

This invention relates to the field of needle-free injector technology, and in particular to an apparatus and method for needle-free injection of local anesthetics into the dermis for infiltration anesthesia. The apparatus includes a receiving space for containing the anesthetic solution; the injection pressure is 14-21 MPa. This invention allows for the design of different needle-free injectors to address the physiological differences in the dermis between men and women, ensuring precise intradermal injection of the anesthetic solution and avoiding entry into the muscle layer. Furthermore, it results in less pain during injection and a longer duration of effect from the onset and exhaustion of the local anesthetic.

To provide a botulinum toxin for treating neuropsychiatric disorders and / or neurological disorders.SOLUTION: Provided is a botulinum toxin for use in the treatment of ASD (autism) in a patient in need thereof. Said treatment comprises administration of botulinum toxin to said patient by subcutaneous / intradermal injection. Administration to adults comprises injecting 2-4 units into and / or around the trigeminal nerve, 2-4 units into and / or around the cervical nerve outside the patient's spine, 2-4 units into and / or around the thoracic nerve outside the patient's spine, 2-4 units into and / or around the lumbar nerve outside the patient's spine, and / or 2-4 units into and / or around the sacral nerve outside the patient's spine. The total dosage of botulinum toxin for an adult human weighing about 150 pounds is no more than about 50 units, adjusted for age, weight, or a combination thereof.SELECTED DRAWING: None

The invention discloses a lymphatic vessel and blood vessel co-localization method under magnetic resonance. According to the method, a mixed contrast agent of gadotetrol and lidocaine is subjected to intradermal micro-injection, and an optimized three-dimensional T1 weighted imaging sequence is adopted for scanning. Under the sequence, the lymphatic vessel presents a high signal due to the contrast agent, and the blood vessel presents a low signal due to the empty flow effect, so that clear distinguishing of the lymphatic vessel and the blood vessel is realized, and imaging and space co-positioning are realized. According to the method, extra injection of vascular contrast agents is not needed, vein pollution can be effectively avoided, and accurate preoperative planning and incision positioning can be provided for lymphatic vein anastomosis.

The invention provides preparation of targeted Anxa2 siRNA and application of the targeted Anxa2 siRNA in drugs for treating atopic dermatitis, and relates to the technical field of biomedicine, and the technical key points are as follows: three groups of targeted Anxa2 gene siRNA molecules are provided, the three groups of targeted Anxa2 gene siRNA molecules can obviously reduce the expression of the Anxa2 gene in vitro, Anxa2-mous-885, Anxa2-mous-768 and Anxa2-mous-338 can effectively reduce the expression of ANXA2 protein in vitro, and the application of the targeted Anxa2 siRNA molecules in the drugs for treating atopic dermatitis in the drugs for treating the atopic dermatitis in the drugs for treating the atopic dermatitis in the drugs for treating the atopic dermatitis is provided. Specific verification experiments prove that Anxa2 expression is obviously increased in transcriptome sequencing, and in-vivo experiments verify that Anxa2 mRNA and protein expression in model mice are obviously increased; the invention successfully designs and proves that three groups of siRNAs capable of effectively inhibiting Anxa2 gene expression can be used for drug research and development; intraepidermal injection of Anxa2-siRNA can relieve pruritus, inflammation and the like caused by MC903 induced atopic dermatitis, and meanwhile expression of Anxa2 mRNA is down-regulated. Therefore, the application of the small interfering RNA to down-regulate or inhibit the expression of the ANXA2 gene and protein is an effective way for treating atopic dermatitis by drugs.

The invention provides a modeling method and application of a simple anaphylactoid purpura animal model. The modeling method comprises the following steps: adaptively feeding SPF rats for 3 days; the hot traditional Chinese medicine is continuously injected into the stomach for 7 days, and 1mL / 100g body mass is injected every day; on the seventh day and the fourteenth day, an abdominal cavity sensitizer is injected to the abdominal cavity of the rat twice; shaving a local area on the back of the rat on the 25th day, performing inhalation anesthesia on the rat, performing warm water local wet compress, and then removing local stubbles by using a scraper; injecting a caudal vein sensitizer into the caudal vein of the rat; and after 30 minutes, intradermal injection of an intradermal sensitizer is carried out, 4-5 points are divided, waiting is carried out for 24 hours, so that the antigen is completely excited, and molding is completed. The hot traditional Chinese medicine comprises the following raw materials: cinnamon, fructus piperis longi and rhizoma zingiberis. The modeling time is shorter, the modeling rate is high, the cost is lower, and blood routine, renal function, immunity and inflammation index detection results and skin and kidney pathological results of model rats are all highly similar to those of simple / blood-heat syndrome anaphylactoid purpura patients.

The invention provides a lipidosome composite adjuvant containing cyclic dinucleotide molecules, the lipidosome composite adjuvant comprises a first lipidosome, a second lipidosome and cyclic dinucleotide, and lipid components of the first lipidosome comprise neutral lipid and monophosphoryl lipid A; the lipid components of the second liposome comprise neutral lipid, cationic lipid and polyethylene glycol lipid. The phospholipid bilayer on the surface of the liposome adjuvant has good biocompatibility and cell uptake promotion effect, the phospholipid bilayer is combined with monophosphoryl lipid A and cyclic dinucleotide molecules to activate TLR4 and STING pathways at the same time, TH1 type immune response is promoted synergistically, cellular immunity is improved, and the liposome adjuvant is especially suitable for disease prevention vaccines mainly based on cellular immunity. The safety is high, and the device is suitable for multi-way inoculation of cavity mucosa, subcutaneous and intradermal / intramuscular injection and the like.

Lymphedema is a chronic condition causes by a lymphatic dysfunction that leads to the accumulation of fluid and fat in the limb. Here, the inventors identified the bioactive peptide apelin as good candidate to restore the lymphatic flow in lymphedema. They found a significant decrease in apelin expression in women lymphedematous arm compared to their normal arm. Using an apelin-knockout mouse model, they confirmed the crucial role of apelin as lymphedema was maintained more than 4 weeks after surgery and was associated with a lack of dermis lymphangiogenesis and increased dermal backflow. The inventors show that intradermal injection of apelin-lentivector significantly reduced limb swelling. This was associated with a reduction of dermis fibrosis and increase in lymphatic density. Importantly, apelin stimulates eNOS-mediated lymphatic pumping via Akt and eNOS phosphorylation in lymphatic endothelial cells (LEC). This was associated with significant increase in E2F8-targeted gene expression through the direct binding of E2F8 on CCBE1 promoter in LEC. Taken together, the results show that apelin plays a key role in lymphedema and thus represents a novel partner for VEGF-C to prevent limb swelling and tissue fibrosis in lymphedema.

The invention provides a spot-fading preparation for corium layer injection, application of the spot-fading preparation, a whitening and spot-fading composition as well as a use method and application of the whitening and spot-fading composition, and relates to the technical field of cosmetics. Based on the unique performance of silk fibroin, the traditional application scope is broken through, and the effect that the silk fibroin injected into the corium layer can obviously fade existing color spots is disclosed for the first time. The silk fibroin is directly injected into the corium layer, the synergistic interaction effect of sodium hyaluronate is combined, the color spots are remarkably faded, meanwhile, the silk fibroin can be matched with external essence containing sodium hyaluronate, tannic acid and polylysine, a complete skin whitening and spot fading scheme combining injection treatment and postoperative care is formed, and the skin whitening and spot fading effect is good. The invention not only overcomes the defects of poor transdermal absorption and non-lasting effect of the traditional whitening component, but also shows the spot fading effect superior to that of the conventional whitening method through a multi-target action mechanism, has the advantages of good biocompatibility, high safety, wide adaptation disease and the like, and provides a new solution for chloasma, sunburn and other intractable hyperpigmentation problems.

This invention provides a needleless intradermal syringe, belonging to the field of syringe technology. It includes a pressure-adjustable grip mechanism and a liquid-driven locking mechanism connected to the pressure-adjustable grip mechanism via a liquid inlet hose. When the pressure of the injection nozzle on the patient's skin reaches the rated pressure, the device can automatically release the locking effect on the elastic injection mechanism. Therefore, it can actively control the pressure of the injection nozzle on the skin to prevent insufficient pressure leading to medication waste or excessive pressure leading to increased patient pain. Furthermore, the device can adjust the rated pressure according to actual conditions, thus possessing pressure-adjustable functionality.